These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3285526)

  • 21. YTGT: A new high-prevalence antigen in the Yt blood group system in two unrelated Native Americans and transfusion management.
    Van Buren NL; Gillen B; Lomas-Francis C; Burgos A; Pease D; Beaver M; Imbryk A; Dugger J; Fugate A; Hebel E; Lodermeier M; Vege S; Westhoff CM
    Transfusion; 2022 Sep; 62(9):1917-1922. PubMed ID: 35904131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the clinical significance of anti-Dob.
    Shirey RS; Boyd JS; King KE; Caturegli PP; Montgomery WM; Ness PM
    Transfusion; 1998; 38(11-12):1026-9. PubMed ID: 9838932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo studies of the long-term 51Cr red cell survival of serologically incompatible red cell units.
    Baldwin ML; Ness PM; Barrasso C; Kickler TS; Drew H; Tsan MF; Shirey RS
    Transfusion; 1985; 25(1):34-8. PubMed ID: 3969699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiolabeled red cell viability. I. Comparison of 51Cr, 99mTc, and 111In for measuring the viability of autologous stored red cells.
    Marcus CS; Myhre BA; Angulo MC; Salk RD; Essex CE; Demianew SH
    Transfusion; 1987; 27(5):415-9. PubMed ID: 3629673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transfusion of multiple units of Js(b+) red blood cells in the presence of anti-Jsb in a patient with sickle beta-thalassemia disease and a review of the literature.
    Yuan S; Ewing NP; Bailey D; Salvador M; Wang S
    Immunohematology; 2007; 23(2):75-80. PubMed ID: 18004938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human erythrocyte acetylcholinesterase bears the Yta blood group antigen and is reduced or absent in the Yt(a-b-) phenotype.
    Rao N; Whitsett CF; Oxendine SM; Telen MJ
    Blood; 1993 Feb; 81(3):815-9. PubMed ID: 8427972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of clinical significance of anti-Ge in an untransfused man.
    Pearson HA; Richards VL; Wylie BR; Bruce D; Watt JM; Wilkie D; Kronenberg H
    Transfusion; 1991; 31(3):257-9. PubMed ID: 2003326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RBCs labeled at two biotin densities permit simultaneous and repeated measurements of circulating RBC volume.
    Mock DM; Lankford GL; Widness JA; Burmeister LF; Kahn D; Strauss RG
    Transfusion; 2004 Mar; 44(3):431-7. PubMed ID: 14996203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Cra: family study and survival of chromium-labeled incompatible red cells in a Spanish-American patient.
    Smith KJ; Coonce LS; South SF; Troup GM
    Transfusion; 1983; 23(2):167-9. PubMed ID: 6836696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of anti-Jra: report of two cases and review of the literature.
    Kwon MY; Su L; Arndt PA; Garratty G; Blackall DP
    Transfusion; 2004 Feb; 44(2):197-201. PubMed ID: 14962310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-transfusion survival of biotin-labeled allogeneic RBCs in adult horses.
    Mudge MC; Walker NJ; Borjesson DL; Librach F; Johns JL; Owens SD
    Vet Clin Pathol; 2012 Mar; 41(1):56-62. PubMed ID: 22251607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case report and review: alloimmunization, delayed hemolytic transfusion reaction, and clinically significant anti-Yt(a) in a patient with Beta-thalassemia/sickle cell anemia.
    Hillyer CD; Hall JM; Tiegerman KO; Berkman EM
    Immunohematology; 1991; 7(4):102-6. PubMed ID: 15946040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Transfusion policy toward a patient with an anti-Cartwright antibody (anti-Yta)].
    Arriaga F; García R; Guinot M; de la Rubia J; García M; Bonanad S; Marty ML
    Sangre (Barc); 1993 Aug; 38(4):327-9. PubMed ID: 8235948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Normal survival in vivo of Yt (a+) red blood cells in a patient with anti-Yta].
    Serrano J; Paniagua C; Sánchez Fayos J; Outeiriño J; Calabuig T; Escudero A
    Sangre (Barc); 1986; 31(6):768-71. PubMed ID: 3563836
    [No Abstract]   [Full Text] [Related]  

  • 35. Red blood cell calcium homeostasis in patients with end-stage renal disease.
    Gafter U; Malachi T; Barak H; Djaldetti M; Levi J
    J Lab Clin Med; 1989 Sep; 114(3):222-31. PubMed ID: 2527934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure of normal red blood cells to become Tn-activated when transfused into a patient with Tn-polyagglutination.
    Reid ME; Ellisor SS; Swanson J; Edwards G; Stanik F
    Am J Med Technol; 1980 Sep; 46(9):670-2. PubMed ID: 7416196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerated removal of antibody-coated red blood cells from the circulation is accurately tracked by a biotin label.
    Mock DM; Lankford GL; Matthews NI; Burmeister LF; Kahn D; Widness JA; Strauss RG
    Transfusion; 2012 May; 52(5):1097-105. PubMed ID: 22023312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Red blood cell survival in long-term dialysis patients.
    Vos FE; Schollum JB; Coulter CV; Doyle TC; Duffull SB; Walker RJ
    Am J Kidney Dis; 2011 Oct; 58(4):591-8. PubMed ID: 21715072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. At(a-) phenotype: description of a family and reduced survival of At(a+) red cells in a proposita with anti-Ata.
    Sweeney JD; Holme S; McCall L; Huett D; Storry J; Reid M
    Transfusion; 1995 Jan; 35(1):63-7. PubMed ID: 7998074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transfusions to group O subjects of 2 units of red cells enzymatically converted from group B to group O.
    Lenny LL; Hurst R; Goldstein J; Galbraith RA
    Transfusion; 1994 Mar; 34(3):209-14. PubMed ID: 8146892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.